The Chinese Pharma Sinovac Biotech plans to start a clinical trial of its experimental vaccine, the CoronoVac, in more than 500 healthy people between the ages of 3 and 17, who will receive two doses and a placebo.
The Chinese Pharma Sinovac Biotech will begin on the 28th of this month to test its candidate vaccine against COVID-19 in adolescents and children, after tests carried out in adults, who are in the final phase, have given positive results.
Ensuring that the vaccine can be applied to the entire population, including children and adolescents, is one of the keys to preventing outbreaks of the virus in schools and daycare centers.
According to a study log published on its website by the U.S. National Library of Medicine, about 552 healthy people ages 3 to 17 will receive two doses of CoronaVac and a placebo, a trial that will combine phases 1 and 2 of trials clinical
Trials will begin in northeast China’s Hebei province, which surrounds Beijing.
The Sinovac vaccine, which in Latin America it is produced in cooperation with the Brazilian institute Butantan, Based in Sao Paulo, it is in the last phase of large-scale adult trials in countries such as Brazil, Indonesia and Turkey.
About 90% of Chinese pharmaceutical company employees worldwide and their families have received their doses, according to the company.
Sinovac said Sept. 9 that the results of its Phase 1 and Phase 2 vaccine trials had shown “good safety and immunogenicity” in healthy adults over 60 years of age.
